Spectrum Announces Publication of Phase III Data on Satraplatin

Spectrum Pharmaceuticals has announced that data from a 50-patient randomized Phase III clinical trial on satraplatin as first-line chemotherapy for hormone-refractory prostate cancer has been published in the peer-reviewed journal Oncology.

Previously reported summary data from the study demonstrated the following in the satraplatin arm: a statistically significant doubling in progression-free survival, and a numerical, although not statistically significant, improvement in median overall survival.